TY - JOUR
T1 - A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice
AU - Ishihara, Akane
AU - Kanatani, Akio
AU - Mashiko, Satoshi
AU - Tanaka, Takeshi
AU - Hidaka, Masayasu
AU - Gomori, Akira
AU - Iwaasa, Hisashi
AU - Murai, Naomi
AU - Egashira, Shin Ichiro
AU - Murai, Takashi
AU - Mitobe, Yuko
AU - Matsushita, Hiroko
AU - Okamoto, Osamu
AU - Sato, Nagaaki
AU - Jitsuoka, Makoto
AU - Fukuroda, Takahiro
AU - Ohe, Tomoyuki
AU - Guan, Xiaoming
AU - MacNeil, Douglas J.
AU - Van Der Ploeg, Lex M.T.
AU - Nishikibe, Masaru
AU - Ishii, Yasuyuki
AU - Ihara, Masaki
AU - Fukami, Takehiro
PY - 2006/5/2
Y1 - 2006/5/2
N2 - Neuropeptide Y (NPY) is thought to have a major role in the physiological control of energy homeostasis. Among five NPY receptors described, the NPY Y5 receptor (Y5R) is a prime candidate to mediate some of the effects of NPY on energy homeostasis, although its role in physiologically relevant rodent obesity models remains poorly defined. We examined the effect of a potent and highly selective Y5R antagonist in rodent obesity and dietary models. The Y5R antagonist selectively ameliorated diet-induced obesity (DIO) in rodents by suppressing body weight gain and adiposity while improving the DIO-associated hyperinsulinemia. The compound did not affect the body weight of lean mice fed a regular diet or genetically obese leptin receptor-deficient mice or rats, despite similarly high brain Y5R receptor occupancy. The Y5R antagonist acts in a mechanism-based manner, as the compound did not affect DIO of Y5R-deficient mice. These results indicate that Y5R is involved in the regulation and development of DIO and suggest utility for Y5R antagonists in the treatment of obesity.
AB - Neuropeptide Y (NPY) is thought to have a major role in the physiological control of energy homeostasis. Among five NPY receptors described, the NPY Y5 receptor (Y5R) is a prime candidate to mediate some of the effects of NPY on energy homeostasis, although its role in physiologically relevant rodent obesity models remains poorly defined. We examined the effect of a potent and highly selective Y5R antagonist in rodent obesity and dietary models. The Y5R antagonist selectively ameliorated diet-induced obesity (DIO) in rodents by suppressing body weight gain and adiposity while improving the DIO-associated hyperinsulinemia. The compound did not affect the body weight of lean mice fed a regular diet or genetically obese leptin receptor-deficient mice or rats, despite similarly high brain Y5R receptor occupancy. The Y5R antagonist acts in a mechanism-based manner, as the compound did not affect DIO of Y5R-deficient mice. These results indicate that Y5R is involved in the regulation and development of DIO and suggest utility for Y5R antagonists in the treatment of obesity.
KW - Antiobesity effect
KW - Receptor occupancy
KW - Y5R-deficient mice
UR - http://www.scopus.com/inward/record.url?scp=33646482230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646482230&partnerID=8YFLogxK
U2 - 10.1073/pnas.0510320103
DO - 10.1073/pnas.0510320103
M3 - Article
C2 - 16636293
AN - SCOPUS:33646482230
SN - 0027-8424
VL - 103
SP - 7154
EP - 7158
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 18
ER -